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oach. AraAbstract The aim of the present work is to investigate the utility of redox chemical delivery pro-
drug approach for the targeted and sustained release of an alkylating anticancer agent in the brain.
The N-methyl-1,4-dihydronicotinate ester of an alkylating nitrogen mustard NM-CDS (4) was syn-
thesized in three step reactions. Structures of all the synthesized compounds were conﬁrmed by UV,
IR, (1H&13C) NMR and CHN elemental studies. In vitro chemical oxidation studies with silver
nitrate of NM-CDS (4) indicated that it can be readily converted into its corresponding quaternary
salt (3) with half life of 8 min. In vitro biological oxidation studies showed facile oxidation in bio-
logical media and rate of oxidation followed pseudo ﬁrst-order kinetics with reasonable half-lives of
32.5 min in rat blood, 24.2 min in human blood and 19.4 min in brain homogenate. The in vivo stud-
ies on Sprague–Dawley rats were performed. The NM-CDS (4) at a dose of 40 mg/kg, was injected
into rats. At selected time intervals, blood samples and the brains were collected and analyzed by
UV spectrophotometer. The results demonstrated that NM-CDS (4) was able to cross the blood–
brain barrier (BBB) at detectable concentration, oxidized to its active quaternary salt (Q-salt) (3)
and sustained there for some period of time. The in silico ADME descriptors required for CNS
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The design of drugs for the chemotherapy of tumors of the
CNS contains numerous challenges. A major difﬁculty in treat-
ing CNS tumors is the drug delivery into the CNS. One of the
major obstacles is the blood–brain barrier (BBB) which is a
primary reason for the non-penetration of drugs. The BBB,
which restricts the delivery of drugs to the brain, is an uninter-
rupted monolayer of tightly connected endothelial cells cover-
ing the luminal surface of cerebral vasculature. Among the
most frequently encountered anticancer drugs, nitrogen mus-
tard (N-mustard) drugs such as chlorambucil, melphalan and
mechlorethamine have been widely utilized in cancer chemo-
therapy (Francisco et al., 2008). These alkylating mustard
derivatives exert their cytotoxic effects by interstrand cross-
linking of DNA via aziridine formation and hence prevent
DNA replication and cell death. Despite their strong antitu-
mor activity, the clinical usefulness of nitrogen mustards has
been restricted due to their non site-speciﬁcity, poor physico-
chemical properties and high chemical reactivity causing toxic-
ity to normal tissues (Denny, 2008). Therefore, the search for
novel nitrogen mustard agents devoid of these side effects con-
tinues to be an active area of research in medicinal chemistry
and various modiﬁcations have been carried out in the last dec-
ade (Kapuriya et al., 2011; Leiris et al., 2010; Li et al., 2013;
Mourelatos et al., 2012; Scutaru et al., 2011). They have been
used clinically for various types of cancer including cervix,
breast and prostate cancer. The possibility of extending their
use to CNS tumor is limited by the fact that, it is highly hydro-
philic and so cannot permeate the BBB. Thus designing and
synthesizing CNS-directed alkylators have been one of the
attractive approaches in the development of potent CNS anti-
cancer agents (Bartzatt, 2004; Genka et al., 1993; Peng et al.,
1975).
One of the most promising approaches for brain delivery is
the prodrug concept of brain-speciﬁc chemical drug delivery
system (CDS) based on redox system analogous to the endog-
enous NADHM NAD+ coenzyme system developed by Bod-
or et al. (1981). According to this, polar drug linked to a
lipophilic 1,4-dihydropyridine carrier could easily penetrate
the BBB. After entry into the brain, this dihydro derivative
is oxidized by (NADMNADH) redox system to a polar
pyridinium salt that cannot egress from the brain which thenN
Cl
Cl
ustard agent (NM) C
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abian Journal of Chemistry (2014),undergoes ester or amide cleavage to release the active drug
and trigonelline. This redox system based chemical delivery
system (CDS) has been the focus of CNS drug delivery efforts
owing to evidence of its role to enhance the selective and sus-
tain delivery of various anticancer agents to the brain (Bodor
et al., 1989; El-Sherbeny et al., 2003; Prokai et al., 2000; Ragh-
avan et al., 1987; Singh et al., 2012a, 2012b, 2013a, 2013b).
CDS of estradiol have advanced to the Phase II clinical trials
for the treatment of postmenopausal syndrome (Tapfer
et al., 2004; Sziraki et al., 2006).
In our earlier study, we have synthesized and studied vari-
ous redox derivatives of nitrogen mustard but compounds
formed were not much stable when stored at room tempera-
ture (Singh et al., 2012b, 2013a). Therefore, there is a need
to design more stable brain targeted nitrogen mustard with
CNS active pharmacokinetic properties.
In the continuation of our work for the synthesis of CNS
active agents (Singh et al., 2011, 2012a, 2012b, 2012c, 2013a,
2013b, 2013c, 2013d), in the present work, we extended our
study to explore chemical delivery system approaches for
alkylating agent to design and synthesize NM-CDS (4) to im-
prove permeability of nicotinic-mustard (NM) alkylating agent
across the brain (Fig. 1). This CDS of nicotinic-mustard (NM)
being lipophilic, is supposed to be entered into the brain and
oxidized into quaternary salt (3). The formed quaternary salt
being hydrophilic is not efﬂuxed from the brain and exerted
its anticancer activity via aziridinium ion formation as shown
in Fig. 2.
2. Experimental section
2.1. Chemistry
The melting points were determined on Veego-programmable
melting point apparatus (microprocessor based) and are
uncorrected. 1H NMR and 13C NMR spectra were obtained
using Bruker Avance-II, 400 MHz spectrometer and are re-
ported in parts per million (ppm), downﬁeld from tetramethyl-
silane (TMS) as internal standard. IR spectra were recorded on
Perkin Elmer model 1600 FT-IR RX-I spectrometer as KBr
disks. The ultraviolet spectra were recorded on Shimadzu,
UV-1800 spectrophotometer. Elemental analyses for CHN
were performed on Thermo-ﬂash EA-1112 CHNS-O analyzer.N
CH3
O
O
N
Cl
Cl
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Design, synthesis, chemical and biological evaluation of brain targeted alkylating agent using reversible 3A computational study of titled compounds was performed for
prediction of ADME properties by QikProp3.2 tools available
in Schro¨dinger 9.0 version (USA) and Molinspiration online
property calculation toolkit (Molinspiration Cheminformat-
ics). Synthesis of 2-{bis(2-chloroethyl)amino}ethyl nicotinate
(2) was carried out as per the modiﬁed reported procedure
(Bartzatt, 2004).
2.1.1. Synthesis of 2-{bis(2-chloroethyl)amino}ethyl nicotinate
(nicotinic-mustard) NM (2)
Thionyl chloride (8 ml, 114.0 mmol) was added to 2.8 g
(22.8 mmol) of nicotinic acid and the mixture was reﬂuxed
for 4 h. The excess thionyl chloride was removed under re-
duced pressure, and 50 ml of dry acetonitrile was then added
to the cold residue followed by 3.4 g (22.8 mmol) of triethanol-
amine and 0.50 ml of triethylamine as catalyst at 0 C. The
mixture was then heated with stirring under mild heat for
1 h. The acetonitrile was removed in vacuo, the residue was
treated with 100 ml of 2% sodium bicarbonate solution and
extracted with ethyl acetate to obtain diol as oil residue. This
material, without further puriﬁcation was chlorinated by an
excess of thionyl chloride (16 ml, 228.0 mmol) in a solution
of acetonitrile and stirred for 3 h. The desired compound (2)
was precipitated overnight from acetonitrile at 10 C. It
was ﬁltered and used for the next reaction without further
puriﬁcation.
Anal.:
Yield= (4.2 g, 64 %)
Rf = 0.56 (Chloroform:methanol, 9:1)
UVmax(methanol): 278 nm
IR KBr (cm1): 3094,2949 (C–H), 1730 (O–C‚O), 1270,
1104(C–N) and 731 (C–Cl).
1H NMR (CDCl3): d (ppm): 2.7–2.8 [m, 6 H, –CH2N(CH2CH2Cl-)2],
3.25 [t, 4H, J=5.7 Hz, –N(CH2CH2Cl)2], 3.75 (t, 2H, J=7.8 Hz,
-OCH2CH2-), 7.4 (t, 1H, J=4.0 Hz, C5pyrH), 8.3 (d, 1H, J=2.0,
C4pyrH), 8.8 (d, 1H, J=5.5, C6pyrH), 9.2 (s, 1H, C2pyrH).
13C NMR (DMSO-d6): d (ppm): 167.0 (C‚O), 150.4 (C-2 pyr),
149.5 (C-6 pyr), 136.8 (C-4 pyr), 127.4 (C-3 pyr), 122.4 (C-5 pyr),
62.2 (O–C), 53.2 (C–N), 56.2 (2xC-N), 43.2 (2xC-Cl).P
r
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The methyl iodide (2.84 g, 0.02 mol) was added to a stirred
solution of 2-{bis(2-chloroethyl)amino}ethyl nicotinate (2)
(2.9 g, 0.01 mol) in acetonitrile (30 ml). The reaction mixture
was reﬂuxed and stirred at room temperature for 24 h. The sol-
vent was removed under reduced pressure to afford the crude
residue of 1-methyl-2-bis(2-chloroethyl)aminoethyl}oxy]car-
bonyl]pyridinium iodide (3).
Anal.:
Yield= (2.5 g, 58 %)
Rf = 0.24 (Chloroform:methanol, 8:2)
UVmax(H2O): 280 nm
IR KBr (cm1): 3045,2978(C–H), 1736 (C‚O), 1265, 1109 (C–N)
and 735(C–Cl).
1H NMR (CDCl3): d (ppm): 2.50-2.70 [m, 6 H, -
CH2N(CH2CH2Cl)2], 3.1-3.29 [t, 4H, J=6.0 Hz, –N(CH2CH2Cl)2],
3.31-3.34 (t, 2H, J=6.5 Hz, -OCH2CH2-), 4.75 (s, 3H, -N
+CH3),
7.4 (t, 1H, J=4.0 Hz, C5pyrH), 8.3 (d, 1H, J=2.0, C4pyrH), 9.34 (d,
1H, J=5.5, C6pyrH), 10.2 (s, 1H, C2pyrH).
13C NMR (DMSO-d6) d (ppm): 168.0 (C‚O), 144.4 (C-2 pyr),
146.4 (C-4 pyr), 148.5 (C-6 pyr), 136.0 (C-3 pyr), 126.4 (C-5 pyr),
62.8 (O–C), 48.8 (N+–CH3), 53.2 (C–N), 56.8 (2xC-N), 43.6 (2xC–
Cl).2.1.3. Synthesis of 2-{bis(2-chloroethyl)amino}ethyl-1,4-
dihydro-1-methylpyridine-3-carboxylate NM-CDS (4)
Quaternary compound (3) (4.3 g, 0.01 mol) was dissolved in a
mixture of deaerated water (200 ml), and ethyl acetate (100 ml)
was cooled to 0 C and stirred under a nitrogen stream. Then
sodium bicarbonate (5.04 g, 0.06 mol) and sodium dithionite
(7.0 g, 0.04 mol) were added portions over a period of
15 min. Stirring was continued, under a nitrogen stream at
0 C, for another 3 h. The organic layer was separated, washed
with cold deaerated water, dried and evaporated in vacuo to
give the crude 2-{bis(2-chloroethyl)amino}ethyl-1,4-dihydro-
1-methylpyridine-3-carboxylate as a sticky gum.ical and biological evaluation of brain targeted alkylating agent using
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rAnal.:
Yield= (1.6 g, 52%).
Rf= 0.48 (Chloroform:methanol, 9:1)
UVmax(CH3OH): 335 nm
IR KBr (cm1) 2958(C–H), 1690 (O–C‚O), 1275, 1110(C–N) and
734 (C–Cl).
1H NMR (CDCl3) d (ppm) : 3.0-3.18 [m, 6 H, –
CH2N(CH2CH2Cl)2], 3.20 (s, 3H, –NCH3), [3.5 (t, 4H, J=5.2 Hz, –
N(CH2CH2Cl)2], 3.64 (t, 2H, J=6.0 Hz, –OCH2CH2-), 4.24 (m,
2H, C4pyrH), 4.7 (m, 1H, C5pyrH), 5.67 (d, 1H, C6pyrH) and 7.0 (s,
1H, C2pyrH).
13C NMR (DMSO-d6) d (ppm): 168.8 (C‚O), 147.2 (C-2 pyr),
130.0 (C-6 pyr), 94.8 (C-3 pyr), 103.4 (C-5 pyr), 25.8 (C-4 pyr), 63.0
(O–C), 52.8 (C-N), 56.4 (2xC-N), 43.2 (2xC-Cl), 39.4 (N-Me).
Anal. calcd for C13H20N2O2Cl2: C% 50.82, H% 6.56, N% 9.12;
Found: C% 50.12, H% 7.05, N% 9.20.2.2. In silico ADME study
A computational study of NM-CDS (4) was performed for
prediction of ADME properties by QikProp3.2 tool available
in Schro¨dinger 9.0 version (USA) and Molinspiration online
property calculation toolkit to get an idea whether the com-
pound has optimum pharmacokinetic properties to enter high-
er phases of the drug development process or not.
2.3. In vitro chemical oxidation studies
2.3.1. Silver nitrate
One ml solution of 5% dihydropyridine derivatives NM-CDS
(4) was prepared in methanol. Then 5.0 ml of saturated meth-
anolic solution of silver nitrate was added to the above solu-
tion. The mixture was shaken and left for 2 min, centrifuged
and the absorbance of the solution was determined after mak-
ing 1.0 ml of solution diluted to 100 ml of methanol and con-
centration determined by the standard curve. The same
procedure was repeated for 4, 6, 8 and 10 min. (D.F. 100).
2.4. Kinetics of oxidation of the dihydro derivatives NM-CDS
(4)
2.4.1. Calibration curves
A UV study of NM-CDS (4) revealed that it obey Beer’s Law
with good correlation coefﬁcient and so the calibration curve
was made from 10 to 50 lg/ml in methanol. The study was
done as per the reported procedure with some modiﬁcations
(El-Sherbeny et al., 2003) at 335 nm got the dihydro derivative
NM-CDS (4).
2.4.2. 100% Whole human blood
Blood was withdrawn from a volunteer shortly before begin-
ning each experiment. The blood was placed in heparinized
tubes and stored in ice until needed, at which time it was incu-
bated at 37 C. In each of ﬁve tubes containing 2 ml of
8.2 · 104 M methanolic solution (stock) of the freshly pre-
pared NM-CDS (4) was added 2 ml of fresh heparinized whole
human blood and the tubes were kept at 37 C in a water bath,
at the end of the time period to be investigated, 6 ml of aceto-
nitrile was added, and the tubes were then shaken vigorouslylease cite this article in press as: Singh, R.K. et al., Design, synthesis, chem
eversible redox prodrug approach. Arabian Journal of Chemistry (2014),and centrifuged, the absorption of the supernatant solution
at their kmax was measured. A reference sample was made by
the addition of 2 ml of methyl alcohol instead of the sample
solution following the same procedure.
2.4.3. 100% Whole rat blood
Blood was withdrawn from rats shortly before beginning each
experiment. The blood was placed in heparinized tubes and
stored on ice until needed, at which time it was incubated at
37 C. In each of ﬁve tubes containing 2 ml of 8.2 · 104 M
of methanolic solution of the freshly prepared dihydro deriva-
tive NM-CDS (4) was added 2 ml of fresh heparinized whole
rat blood and the tubes were kept at 37 C in a water bath,
at the end of the time period to be investigated, 6.0 ml of ace-
tonitrile was added, and the tubes were then shaken vigorously
and centrifuged, the absorption of the supernatant solution at
their kmax was measured. A reference sample was made by the
addition of 2 ml of methyl alcohol instead of the sample solu-
tion following the same procedure.
2.4.4. Brain homogenate
Rat brain tissue (2.0 g) was homogenized in 10.0 ml of phos-
phate buffer (pH 7.4) in an ice bath. An aliquot of the brain
homogenate (2 ml) was added to each of ﬁve tubes containing
2 ml of 8.2 · 104 M methanolic solution of the freshly pre-
pared dihydro derivative NM-CDS (4) and tubes were kept
at 37 C in a water bath. At the end of the time period to be
investigated, 6.0 ml of acetonitrile was added and tubes were
then shaken vigorously and centrifuged, the absorption of
the supernatant solution at their kmax was measured at appro-
priate time intervals. A reference sample was made by the addi-
tion of 2 ml of methyl alcohol instead of the sample solution
following the same procedure.
2.5. Stability study on storage
The NM-CDS (4) was tested for stability at different storage
conditions by the published method (Al-Obaid et al., 2006).
Samples from the prepared NM-CDS (4) was dried and stored
in dark brown bottles and stored under nitrogen and dry con-
ditions at room temperature (25 C) and in the refrigerator. At
2 month intervals, each sample was analyzed for its content of
the NM-CDS using UV spectral analyses.
2.6. In vivo animal evaluation
The experimental protocols were approved by the Institutional
Animal Ethics Committee of Shivalik College of Pharmacy,
Nangal and a written permission from in house ethics commit-
tee has been taken to carry out (Reference No. 1080/C/07/
CPCSEA having protocol no 6.2.1. dated 26 Feb 2011) and
complete this study at Shivalik College of Pharmacy, Nangal
as per the published procedure (El-Sherbeny et al., 2003). Fe-
male Sprague Dawley rats were used in this study. Rats were
randomly divided into ﬁve groups (n= 3) for different sam-
pling time. Each group contained three rats of 150–250 g each.
Each animal was injected with NM-CDS (4) in a mixture of
DMSO:phosphate buffer (pH 7.4, 2:1) at a concentration of
25 mg/ml through the tail vein at a dose of 40 mg/kg. The rats
were placed in a cage with free access to food and water. At the
appropriate time interval (15, 30, 60, 100 and 150 min), threeical and biological evaluation of brain targeted alkylating agent using
http://dx.doi.org/10.1016/j.arabjc.2013.12.008
Design, synthesis, chemical and biological evaluation of brain targeted alkylating agent using reversible 5rats were sacriﬁced by CO2 inhalation, decapitated and 1 ml
blood was collected from the trunk and stored in heparinized
tubes. Meanwhile, the brain was removed, weighed and cov-
ered with aluminum foil. The blood samples and the brains
were kept in a deep freezer until assayed. Each brain was
homogenized with 1.0 ml of water, 4.0 ml of acetonitrile was
added and the mixture was homogenized again. Blood samples
were mixed with 4 ml of acetonitrile, for protein precipitation,
and vortexed at high speed for 1 min. Both brain homogenate
and blood samples were centrifuged at 20,000 RPM for 10 min
and the supernatants were analyzed under UV spectrophotom-
eter at speciﬁed wavelength of quaternary salts. The calibra-
tion curve of the quaternary salt (3) in 2 % aqueous
methanol was plotted, the mean best-ﬁt linear regression equa-
tion derived and used to estimate the concentration of the qua-
ternary salt 3 at different time intervals.
2.7. NBP alkylation assay
Q-salt (3) of NM-CDS (4) was checked for their NBP alkylat-
ing activity by the procedure mentioned before (Balazs et al.,
1970). Chlorambucil (1.0 mg) and synthesized compounds
were dissolved in 20.0 ml of 95% EtOH. A 1.0 ml aliquot of
this solution was placed in a 5.0 ml volumetric ﬂask together
with 1.0 ml of NBP solution (3.55 g/50 ml of acetone) and
1.0 ml of buffer solution (1.0 g of potassium hydrogen phthal-
ate/100 ml of water). The ﬂask was kept at 85 C in a water
bath for 30 min. The solution was cooled immediately for 2–
3 min in an ice bath and 0.1 ml of a KOH solution (1.4 g/
25 ml of 95% EtOH) was added. The solution was diluted to
5.0 ml with 95% EtOH and shaken. After 2 min, the absor-
bance from 540 to 560 mm was recorded. This procedure
was used with varying the heating time to obtain the data tab-
ulated in Table 6. The procedure was repeated thrice for com-
pound 3.
K values (i.e. rate constant) were calculated by the formula.
K ¼ ðA2  A1=T2  T1Þ
where A= absorbance at 545 nm and T= heating time.N
COOH
N
COCl
(1)
(i)
(iv
N
(4)
CH3
O
O
N
Cl
Cl
(ii)
NM-CDS
Scheme 1 Reagents and Conditions: (i) thionyl chloride, (ii) triethan
bicarbonate, sodium dithionite.
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presence of excess of NBP, they are proportional to (but not
the same as) the pseudo-ﬁrst-order rate constants for NBP
alkylation.
Half life of compound was calculated by the formula:
t1=2 ¼ 0:693=K3. Result and discussion
3.1. Chemical characterization
The major steps for the synthesis of the CDS-mustard agent
are presented in Scheme 1. Synthesis of N-{bis(2-chloro-
ethyl)amino}ethyl nicotinate (2) was carried out as per modi-
ﬁed reported procedure (Bartzatt, 2004). Initially, the
carboxyl group of nicotinic acid is activated utilizing thionyl
chloride, which forms the more reactive acyl halide (1). This
acyl halide was reacted with triethanolamine to obtain inter-
mediate, N-{2-bis(2-hydroxyethyl}aminoethyl}oxy}carbonyl
pyridine compound which without further puriﬁcation was
chlorinated by thionyl chloride to obtain the nicotinic-mustard
(2). The compound (2) was then quaternized using methyl
iodide in acetonitrile to give the quaternary salts (3). The
obtained quaternary salt (3) was then subjected to reduction
process using sodium dithionite in alkaline medium, to give
the corresponding dihydro compound NM-CDS (4).
3.2. In silico ADME studies
The NM-CDS (4) is essentially intended to act on CNS tumor,
the BBB must be crossed for its effect to be executed. So all
the physicochemical parameters were selected which affect
blood–brain barrier (BBB). Lipophilicity (ratio of a molecule’s
solubility in octanol to solubility in water) was measured
through logP. logP value was linked to blood–brain barrier pen-
etration and utilized to predict permeability. The logP value of
NM-CDS (4) is determined by several algorithmic approaches
(ClogP, miLogP, QP logP o/w) (Table 1). All methods showN
O
O
Nicotinic-mustard (NM) 
                 (2)
)
N
Cl
Cl
O
O
N
Cl
Cl
N
CH3
I
Q-salt (3)
(iii)
olamine, thionyl chloride (iii) methyl iodide, acetone (iv) sodium
ical and biological evaluation of brain targeted alkylating agent using
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Table 1 Various physicochemical parameters obtained by various tools important for CNS activity.
Compound miLogPa ClogPb QP logP o/wc QP logSc QP logBB3 PSAa
<5 <5 (2.0–6.5) (6.5–0.5) (3 to1.2) (A2)
NM-CDS (4) 1.87 2.09 3.55 3.82 0.39 32.78
MCL 1.55 1.20 1.967 1.122 1.173 3.2
CBL 3.97 3.63 4.67 5.347 0.583 40.5
www.molinspiration.com/cgi-bin/properties.
a Calculated by method of Molinspiration.
b Calculated by ChemDraw Ultra version 8.0.
c Calculated by QikProp.
Table 2 In silico Pharmacokinetic parameters with their optimum range important for CNS activity and oral bioavailability obtained
by QikProp tool.
Descriptors MCEa CBLb NM-CDS (4)
CNS (2 to +2) 2 1 1
M.WT< 500 156.055 304.216 307.219
PSA (7.0–200) 5.6 55.2 29.0
Donar HB (0–6) 0 1 0
Accept HB (2.0–20) 2 3 4.5
QP logP o/w (2.0–6.5) 1.967 4.671 3.549
Rot bond (0–15) 2 7 4
QP log S (6.5–0.5) 1.122 5.347 3.82
QPPCaco < 25 poor > 500 good 2300.154 227.915 748.023
QP logBB (3.0–1.2) 1.173 0.583 0.398
QPPMDCK< 25 poor > 500 good 8513.882 802.855 2503.365
Metablsm (1–8) 1 3 3
% Hu Ab > 80% high < 25% poor 100 96.495 100
N and O< 2–15> 1 3 4
Violation of rule of ﬁve (max 4) 0 0 0
Violation of rule of three (max 3) 0 0 0
a Mechlorethamine.
b Chlorambucil.
6 R.K. Singh et al.a signiﬁcant increase of lipophilic nature for the NM-CDS (4).
Literature survey suggests that Polar Surface Area (PSA) is a
measure of amolecule’s hydrogen bonding capacity and its value
should not exceed certain limit if the compound is intended to be
CNS active (Clark, 1999; Iyer et al., 2002; Kelder et al., 1999;
Palm et al., 1996). Themost active of CNS drug have PSAof less
than 70 A2. The value of PSA for NM-CDS is 32.78 indicating
good penetration to the BBB.
Hydrophilicity (logS) and logBB are the other principle
descriptors to be identiﬁed as important for CNS penetration.
Experimental values of log BB published cover the range from
about 2.00 to +1.04. Within this range, compounds with log
BB > 0.30 cross the BBB readily, while compounds with a log
BB < 1.00 are poorly distributed to the brain (Iyer et al.,
2002). The logBB values for our NM-CDS (4) (0.398) were
found to be greater than 0.30, indicating excellent potential
for BBB penetration.
Other physicochemical descriptors obtained by QikProp
presented in Table 2 support the clinical potential of NM-
CDS (4). The physically signiﬁcant descriptors were analyzed
for mechlorethamine, chlorambucil and NM-CDS (4) for the
CNS activity. QPPMDCK predicted apparent MDCK cell
permeability in nm/s. MDCK cells are considered to be a goodPlease cite this article in press as: Singh, R.K. et al., Design, synthesis, chem
reversible redox prodrug approach. Arabian Journal of Chemistry (2014),mimic for the BBB. The higher the value of MDCK cell, the
higher is the cell permeability. MDCK value of NM-CDS (4)
is >2500 showing good BBB penetration which is desirable.
The NM-CDS has polarities that enabled better permeation
and absorption, as revealed by the number of H-bond donors
and H-bond acceptors. The predicted drug likeliness of the
NM-CDS (4) follows Lipinski’s ‘‘Rule of Five’’ (Lipinski
et al., 1997), all four parameter values for a compound i.e.
LogP< 5, H-bond donors <5 , H-bond acceptors <10 and
molecular weight <500. According to Jorgensen’s rule of three
(Jorgensen, 2009), there should be QPlogS > 5.7, QPPCac-
o > 22 nm/s, # Primary Metabolites <7. In accordance with
the data obtained (Table 2), NM-CDS (4) has no violation
of Jorgensen’s rule of three and all values were within the lim-
its which shows that NM-CDS (4) has a potential to effectively
cross the BBB.3.3. In vitro chemical and biological oxidation and storage
stability studies
The prepared NM-CDS (4) was subjected to various chemical
and biological investigations to evaluate its ability to cross theical and biological evaluation of brain targeted alkylating agent using
http://dx.doi.org/10.1016/j.arabjc.2013.12.008
Figure 3 Concentration (lg/ml) against time of NM-CDS (4) in
whole human blood, whole rat blood and brain homogenate.
Figure 4 Log concentration against time of NM-CDS (4) in
whole human blood, whole rat blood and brain homogenate.
Table 3 Rates of oxidative conversion in biological ﬂuids of
redox derivatives NM-CDS (4) to quaternary pyridinium salt
(3).
Medium NM-CDS (4)ﬁ q-salt (3)
n k · 102 min1 t1/2 min
Silver Nitrate 6 9 ± 0.05 8.3
Whole Human Blood 4 4.47 ± 1.6 32.5
Whole Rat Blood 4 9.6 ± 2.4 24.2
Brain Homogenate 3 5.46 ± 2.7 19.4
S.D. is ±10 % of the presented values.
Table 4 Stability of NM-CDS (4) upon storage.
Conditions NM-CDS (4)
Zero Days 60 Days % Decomposed
Room Temperature (25 C) 1.125 0.967 14
Refrigerator (4 C) 1.125 1.080 4
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nary salts (3). In this study UV spectrophotometer was used to
detect and monitor the oxidation of the tested NM-CDS (4).
All the kinetic studies were carried out in triplicate. The K
values from the plot were calculated separately and average
K and S.D. value was determined. Figs. 3 and 4 show the re-
sults of such an investigation. Pseudo-ﬁrst order rate constants
for the disappearance of compounds in biological media were
determined by linear regression analysis from plot of log NM-
CDS (4) versus time. Quaternary salt (3) which was thought to
be converted from NM-CDS (4), did not interfere with the
absorption of NM-CDS (4) because its kmax was found to be
280 nm, which was considerably different from those of NM-
CDS (4) which is 335.
Table 3 shows the calculated half-lives for NM-CDS in dif-
ferent media. The in vitro oxidation studies with AgNO3 indi-
cated the facile oxidative conversion of the NM-CDS (4) into
the corresponding quaternary salt (3) with the higher oxidation
rate (K= 0. 083 ± 0.08, t1/2 = 8.3 min). The NM-CDS was
quite stable in whole human blood with K value of 0.0213
± 2.2 and t1/2 of 32.5 min than rat blood (t1/2 = 24.2 min).
This may be due to much higher enzymatic activity, particu-
larly esterase activity, observed in rats than in human blood
(Phelan and Bodor, 1989). The NM-CDS (4) was readily oxi-
dized in rat brain homogenate with K value of 0.0357 ± 3.2
and t1/2 of 19.4 min. The results of these in vitro stability tests
met the requirement of the redox chemical delivery system and
hence further checked for in vivo study. (See. Table 5).
A parallel study of the storage stability of NM-CDS (4) at
room temperature and in the refrigerator (4 C) over a periodFigure 5 The concentration of Q-salt (3) in the brain (lg/g) and
blood (lg/ml)) of rats after administration of NM-CDS (4).
Table 5 Mean Concentration of the quaternary salt (3) in
brain homogenate (lg/g) and blood (lg/ml) of rats after
administration of NM-CDS (4) (40 mg/kg).
Time (min.) Mean concentration ± SD
Blood (lg/ml) Brain homogenate (lg/gm)
15 85 ± 4.5 9 ± 5.8
30 43 ± 6.8 32 ± 3.6
60 12 ± 7.4 58 ± 2.4
100 Undetectable 72 ± 6.9
150 Undetectable 65 ± 7.5
No. of determination(n) = 3.
ical and biological evaluation of brain targeted alkylating agent using
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Figure 6 NBP reacts speciﬁcally with quaternary salt (3) of NM-CDS (4) to produce chromophore which upon basiﬁcation with sodium
hydroxide (see broken oval) gives purple color and has a strong absorbance peak at 541 nm.
Table 6 The alkylating activity (NBP assay) of the quaternary
salt (3) of NM-CDS (4).
Compounds kmax Temp.(C) K min1 · 102 t1/2 (min)
Q-salt (3) 550 65 2.9 ± 0.158 18.6
Chlorambucil 560 85 10.65 ± 0.122 6.5
8 R.K. Singh et al.of 60 days was conducted as per the reported procedure (Al-
Obaid et al., 2006). The acetonitrile solution of the NM-CDS
(4) was UV checked after the speciﬁed time period (Table 4).
3.4. In vivo biological oxidation study
The stability of the CDS is important in determining their suit-
ability to act as a delivery system. NM-CDS (4) at a dose of
40 mg/kg was injected into rats. At selected time intervals,
blood samples and the brains were collected. The results are
shown in Fig. 5 and Table 5. The analysis of blood samples ta-
ken after 15 min proved the presence of quaternary salt (3c) in
high concentration (85 lg/ml) with low amount of (3c) (9 lg/g)
in the brain. With time, the concentration of quaternary salt 3c
declined rapidly in blood and was not detected at 100 min. On
the other hand, the concentration of 3c increased steadily in
the brain, reaching its maximum at 100 min (72 lg/g) after
administration, followed by a steady decline indicating the sus-
tained conversion into alkylating quaternary salt (3c). (See
Fig. 5).
3.5. NBP alkylating activity assessment
The ﬁnal compound NM-CDS (4) in the form of its quaternary
salt (3) was evaluated for its alkylating activity using 4-(4-
nitrobenzyl) pyridine (NBP) as an analytical reagent. It is
hypothesized that there is a correlation between the chemical
alkylating activity and anti-tumor activity (Gomez-Bombrelli
et al., 2012). The reaction was determined at 600C in 50%
aqueous acetone using spectrophotometric quantitation. The
NBP reacts with quaternary salt (3) to form Q-mustard-NBPPlease cite this article in press as: Singh, R.K. et al., Design, synthesis, chem
reversible redox prodrug approach. Arabian Journal of Chemistry (2014),adduct which gives a purple color upon basiﬁcation. The inten-
sity of the produced color measured by UV spectrophotometer
as absorbance is directly proportional to the degree of alkyl-
ation (Fig. 6). This method differentiates between the reactivity
of the quaternary salt (3) under speciﬁed conditions using
chlorambucil as positive control (Table 6).
4. Conclusion
The present study demonstrates the synthesis and evaluation of
the redox derivative of alkylating agent. The preliminary chem-
ical and biological in vitro studies revealed that the brain target-
ing could be possible with this compound. The in vivo study
showed that NM-CDS (4) was able to cross the BBB and sus-
tained there for some period of time. The alkylating potency of
quaternary salt (3) has been evaluated by NBP alkylating assay.
In silico pharmacokinetic prediction revealed that NM-CDS (4)
is showing drug likeliness withmarked lipophilicity, oral absorp-
tion and optimum CNS activity. NM-CDS (4) is not violated
from Lipinski’s rule of 5 and Jorgensen rule of 3, so it is able
to enter into the next phase of drug. This redox chemical delivery
approach opens new avenue for drug delivery of alkylating agent
which better meets the needs of anticancer research.Acknowledgments
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